Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28656520 | 0.87 | CA12 (0.36) | CA12CA9CYP2A6 | |
| SCHEMBL28658792 | 0.74 | CA2 (0.42) | CA12CA9PTGS2TRPA1 | |
| SCHEMBL5807597 | 0.72 | CA12 (0.49) | CA12CA9PTGS2P2RY6CYP2A6 | |
| SCHEMBL29757278 | 0.67 | KDM4E (0.36) | TRPA1 | |
| SCHEMBL8513761 | 0.67 | — | — | |
| SCHEMBL3700875 | 0.66 | CA12 (0.49) | CA12CA9PTGS2P2RY6CYP2A6 | |
| SCHEMBL30860504 | 0.66 | CA12 (0.49) | CA12CA9PTGS2P2RY6CYP2A6 | |
| SCHEMBL6369121 | 0.66 | CA12 (0.49) | CA12CA9PTGS2P2RY6CYP2A6 | |
| SCHEMBL11619301 | 0.65 | CA12 (0.47) | CA12CA9CYP2A6 | |
| Hydrochloric Acid SCHEMBL27286662 | 0.64 | CA12 (0.47) | CA12CA9PTGS2P2RY6CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113508118-A | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2021-10-15 | — | — | CN | claimed |
| CN-113508118-A | Fused tricyclic compounds useful as anticancer agents | 阿斯利康(瑞典)有限公司 | 2021-10-15 | — | — | CN | disclosed |